
South African President Cyril Ramaphosa launched a nearly $200 billion investment drive aimed at accelerating economic recovery and industrialization in the face of growing worry over the impact of the Iran war on the continent’s biggest economy.
For more than a decade, South Africa’s economy has barely grown, leaving it with crumbling infrastructure and the need to create jobs in a country where one in three people are unemployed. Ramaphosa’s pitch to investors in Johannesburg this week was that South Africa has fixed the worst bottlenecks: He said the country is opening key sectors to private capital and is ready for large scale investments.
Ramaphosa said the effort will run through 2030 with delegates at the South African Investment Conference pledging $53 billion across 31 projects spanning energy, logistics, manufacturing, and digital infrastructure. They include Coca-Cola’s $1 billion expansion plan, and a $3.6 billion commitment from Sasol — the world’s biggest maker of fuel from coal — to upgrade operations.
LATEST POSTS
- 1
Mars orbiter sees 'butterfly' crater spread its wings on the Red Planet - 2
3 moms, 3 countries, 1 very familiar problem: Why child care costs still don't add up for families - 3
Palestinians tell BBC they were sexually abused in Israeli prisons - 4
Two IDF officers, civilian face indictment in alleged Gaza aid-truck smuggling scheme - 5
What to watch for in weight loss drugs in 2026
‘RuPaul's Drag Race’ Season 18: How to watch without cable, premiere time, cast list and more
Artemis II astronauts channel Apollo 8 with a striking Earthset photo
Exploring the Difficulties of Co-Nurturing: Individual Bits of knowledge
Churches and politicians in South Sudan call for 'lasting peace' in Easter messages
Instructions to Safeguard Your Speculations In the midst of Changing Disc Rates
Why most Jewish Israelis back the death penalty for terrorists
10 Work Valuable chances to Assist with supporting Your Advanced degree
Oprah Winfrey's Favorite Wellness Destination Is A Luxurious Italian Retreat
Impact of NIH funding reductions felt in cancer and infectious disease trials













